{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:24:35Z","timestamp":1770506675272,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":853,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1002\/hep.26155","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T09:19:28Z","timestamp":1353662368000},"page":"1691-1693","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come"],"prefix":"10.1097","volume":"57","author":[{"given":"Nisanne S.","family":"Ghonem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20241201","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0026-0495(93)90056-T","article-title":"The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities.","volume":"42","author":"Day","year":"1993","journal-title":"Metabolism"},{"key":"R2-4-20241201","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.","volume":"57","author":"Honda","year":"2013","journal-title":"HEPATOLOGY"},{"key":"R3-4-20241201","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery.","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"R4-4-20241201","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis.","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R6-4-20241201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-4-20241201","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis.","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R9-4-20241201","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study.","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"key":"R10-4-20241201","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of longterm outcome.","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R11-4-20241201","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1210\/mend.14.1.0409","article-title":"The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.","volume":"14","author":"Jones","year":"2000","journal-title":"Mol Endocrinol"},{"key":"R12-4-20241201","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1021\/jm9804127","article-title":"N(2Benzoylphenyl)Ltyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.","volume":"41","author":"Henke","year":"1998","journal-title":"J Med Chem"},{"key":"R13-4-20241201","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/mol.108.052928","article-title":"Bezafibrate at clinically relevant doses decreases serumliver triglycerides via downregulation of sterol regulatory elementbinding protein1c in mice: a novel peroxisome proliferatoractivated receptor alphaindependent mechanism.","volume":"75","author":"Nakajima","year":"2009","journal-title":"Mol Pharmacol"},{"key":"R14-4-20241201","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bcp.2008.04.001","article-title":"Cholesterollowering effect of bezafibrate is independent of peroxisome proliferatoractivated receptor activation in mice.","volume":"76","author":"Nakajima","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"R15-4-20241201","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-003-0704-1","article-title":"Fibrates modify the expression of key factors involved in bileacid synthesis and biliarylipid secretion in gallstone patients.","volume":"59","author":"Roglans","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-4-20241201","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11010-008-0001-5","article-title":"Lipidactivated transcription factors control bile acid glucuronidation.","volume":"326","author":"Barbier","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"R17-4-20241201","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1440-1746.2011.06837.x","article-title":"No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!.","volume":"26","author":"Halliday","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"RU18-4-20241201","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"RU19-4-20241201","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"RU20-4-20241201","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","article-title":"Longterm effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis.","volume":"41","author":"Ohmoto","year":"2006","journal-title":"J Gastroenterol"},{"key":"RU21-4-20241201","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","article-title":"Effect of bezafibrate in primary biliary cirrhosis: a pilot study.","volume":"21","author":"Ohmoto","year":"2001","journal-title":"Liver"},{"key":"RU22-4-20241201","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.","volume":"41","author":"Kita","year":"2006","journal-title":"J Gastroenterol"},{"key":"RU23-4-20241201","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.","volume":"44","author":"Hazzan","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"RU24-4-20241201","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","article-title":"Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.","volume":"26","author":"Takeuchi","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"RU25-4-20241201","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study.","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"RU26-4-20241201","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.metabol.2008.08.005","article-title":"Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis1 deficiency manifesting progressive familial intrahepatic cholestasis.","volume":"58","author":"Nagasaka","year":"2009","journal-title":"Metabolism"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201305000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:48:09Z","timestamp":1733060889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201305000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26155","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}